Clear Scientific News

Chicago, IL | Oct 2026 Co-founders, Shekar Shetty, Peter Howe, and Winston Henderson attended the 2026 American College of Emergency Physicians (ACEP) Scientific Assembly in Chicago from October 5–8. The conference convenes emergency medicine professionals nationwide for practice-changing education, hands-on training, research, innovation, and collaboration. The 2026 program highlights advances in emergency diagnosis and treatment, resuscitation and critical care, artificial

Cambridge, MA | Oct 2026 PRNewswire/-- Clear Scientific, Inc. announced positive top-line results from its Phase 2 trial of CS-1103, a small-molecule sequestrant that immediately binds and inactivates fentanyl, subsequently accelerating its removal from the body into urine. The results provide validation of CS-1103's novel mechanism of action. The trial met all endpoints, with CS-1103 accelerating the removal of fentanyl in human subjects and showing a favorable safety profi

Cambridge, MA | August 2026 A novel drug sequestrant-based therapeutic candidate reverses methamphetamine-induced hyperthermia and hypermetabolism and abates multiorgan toxicity in rats - ScienceDirect In a preclinical study funded by the National Institute on Drug Abuse, CS-1103 protected against methamphetamine overdose, for which there are currently no medications. This pioneering work was conducted by Dr. Joe Cotten, MD, PhD and Dr. Elie Adam, PhD at Mass General Brigham

Cambridge, MA | August 2026 Clear Scientific, a clinical-stage biopharmaceutical company, was awarded a $5.2M award from the NIH’s National Institute on Drug Abuse to continue the development of CS-1103 through Phase 2 clinical trials for the reversal of methamphetamine intoxication. Illicit stimulant use, especially methamphetamine, is a major public health crisis for which there are no FDA-approved therapeutics. Clear Scientific has raised an additional $2.6M in an open SA

Portland, OR | June 2026 Piercen Oliver PhD, VP of R&D and Xinhua Li PhD, Executive Vice President Drug Development of Clear Scientific Inc. presented at the 88th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD) in Portland, Oregon, June 13th-17th. CPDD provides a national and international forum for scientists of diverse backgrounds to advance the understanding of molecular-neurobiological aspects of addictive disorders and improve and develop

Boston, MA | June 2026 https://www.youtube.com/live/kic6w7fgBQI?si=9ONxIWdNwEok4Nl1&t=7552 Clear Scientific’s CEO, Shekar Shetty, and General Counsel, Winston Henderson, joined the June 9th Boston’s GBH radio show, The Curiosity Desk hosted by Edgar B. Herwick III.  GBH’s newest show is live weekday afternoons from 1 to 2 p.m. EST and focuses on conversations, insights and profundities about the world we live in. Tune in to listen to the Clear Scientific team discuss the dev

Kiawah Island, SC | June 2026 Peter Howe, CFO, and Shekar Shetty, CEO, from Clear Scientific attended the 2026 Coastal Emergency Medicine Conference (CEMC) June 4th-6th in Kiawah Island, South Carolina. For over a decade, this American College of Emergency Physician (ACEP) chapter has hosted Emergency Physicians from Georgia, South Carolina and North Carolina as well as associated professionals to connect, share practice-changing education, and engage in forward-thinking

Cambridge, MA | May 2026 https://www.criver.com/eureka/pac-man-chemistry-breakthrough-treating-methamphetamine-overdose Clear Scientific’s CEO, Shekar Shetty, and General Counsel, Winston Henderson, joins the May 5th podcast, episode 116 of Eureka: A Dose of Science, a multimedia platform that continually searches for creative ways to talk about science, including breaking news science and the people behind it. “What if one shot could reverse a meth overdose? In this episod

Cambridge, MA | May 2026 PRNewswire/ -- Clear Scientific Inc., a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted its lead asset, CS-1103, Fast Track designation for treatment of acute fentanyl intoxication. Clear Scientific is focused on the development of first-in-class small molecules to reverse acute intoxication from drugs of abuse and accelerate their clearance from the body, preventing further har

Cambridge, MA | April 2026 On April 17, 2026, Piercen Oliver PhD, VP of Research & Development of Clear Scientific Inc. presented at the Inaugural UC Summit on Methamphetamine: Advancing Research, Policy, and Public Health. The UC Summit is committed to being an outstanding beginning to building region wide efforts that address the challenges of intervention on methamphetamine use in Riverside County and throughout California. Dr. Oliver’s talk centered around Treatment Inn

Dubai | February 2026 Clear Scientific, represented by Peter Howe, Co-Founder and CFO participated in the World Health Expo (WHX) Dubai 2026, a global healthcare platform focusing on life sciences innovation in the Middle East North Africa (MENA) region. This conference underscores the growing importance of cross border engagement between the Middle East and the Americas in accelerating life sciences investment, commercialization, and innovation. Clear Scientific participat

Cambridge, MA | September 2025 PRNewswire/ -- Clear Scientific Inc., a clinical stage biopharmaceutical company focused on the development of first-in-class small molecules to reverse acute intoxication from methamphetamine, announced today that the U.S. Food and Drug Administration (FDA) has granted its lead asset, CS-1103, Fast Track designation for treatment of acute methamphetamine intoxication. The FDA grants investigational medicines Fast Track designation to facilitat

Boston, MA | July 2025 On July 31, Winston Henderson, General Counsel at Clear Scientific Inc., joined a panel with Carl Berke (Mass General Brigham Ventures), Michael Freni (AI Digital Innovation Fund), and moderator Sherene Shenouda (Mass General Brigham Innovation) to discuss funding innovation in the Substance Use Disorder (SUD) space. The panel explored how stakeholders—including investors, researchers, hospital leaders, and policymakers—can collaborate to advance and c

New Orleans, Louisiana | June 2025 On June 16, 2025, Piercen Oliver PhD, VP of R&D and Xinhua Li PhD, Executive Vice President Drug Development of Clear Scientific Inc., a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, presented a poster titled Development of CS-1103 a First-in-Class Treatment for Methamphetamine Intoxication at the 87th in New Orleans, LA. The presentation described the chemistry, anticipated benefits, Phase 1 resu

Hamburg, Germany | May 2025 Shekar Shetty, Chief Executive Officer of Clear Scientific Inc., a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, was invited to deliver a keynote address at the inaugural International Society of Addiction Medicine’s (ISAM) Global Addiction Therapeutics Innovation Day event, which was held in Hamburg, Germany, on May 25, 2025. The event comprised a full-day pre-conference session preceding the ISAM 2025 Annual

San Antonio, TX | March 2025 On March 23, 2025, Dr. Xinhua Li, Executive Vice President of Clear Scientific Inc., a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, presented a keynote talk at the 18th Annual Conference in Behavior, Biology, and Chemistry Translational Research in Substance Use Disorders held in San Antonio, Texas. This conference centers on the translational aspects of substance use disorder research among chemists, biolog

Rockville MD | Dec 2024 On December 17-18, 2024, Dr. Xinhua Li and Dr. Mitch Zakin of Clear Scientific Inc., a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, presented a poster titled “A Broad-Spectrum Therapeutic as a Countermeasure Against Acute Opioid and Polydrug Intoxication” at the Advances in Developing Medical Countermeasures Against Opioids and Drug-Induced Respiratory Depression Conference in Rockville, Maryland. The growing public heal

Las Vegas, NV | Oct 2024 Peter Howe and Charlotte Leggett from Clear Scientific attended the 2024 American College of Emergency Physicians (ACEP) Scientific Assembly in Las Vegas, Nevada. The conference hosts an environment for physicians to connect, share practice-changing education, and engage in forward-thinking collaboration. Through physician conversation, it is clear that methamphetamine intoxication has high prevalence across a variety of United States regions. Some

Cambridge MA | Sept 2024 Clear Scientific, a clinical-stage biopharmaceutical company, today announced a $3M award from the National Institute on Drug Abuse of the NIH to support continued development of its candidate sequestrant-based therapeutic to reverse overdose from combinations of fentanyl and xylazine. The therapeutic immediately inactivates fentanyl and xylazine by binding and encapsulation, rapidly reversing their toxic effects, and accelerates their clearance from